Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 22, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 21, 2026 — +27.8% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$900.00 – $930.00Entry zone — fair-value band

$919.97Published — price the day we called it

$1,057.96Target — the price the thesis aimed for

$1,249.45Peak — highest point inside the window, not a realized return

$1,175.41Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 30 days.

At window close

+27.8%

realized, from the publication price to the last close inside the window

Peak gain

+35.8%

peak, from the publication price — not a realized return

S&P 500, same window

+5.5%

SPY over the identical days, dividend-adjusted

Window close

$1,175.41

last close inside the window, ended July 21, 2026

Peak price

$1,249.45

peak on July 7, 2026 — not a realized return

Days to target

The thesis — published April 22, 2026

Predicted growth

+15%

over the measurement window

Target price

$1,057.96

the price the thesis aimed for

Entry zone

$900.00 – $930.00

the fair-value band we waited for

Price at publication

$919.97

published April 22, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly mixes steady demand with growth potential over the next quarter. Positive trial results and wider GLP-1 availability point to stronger sales for obesity and diabetes drugs, and the stock's recent pullback makes the timing more reasonable. The company still has momentum in its key drug areas, but recent headlines mean patience is helpful.

Primary drivers

Obesity and diabetes drugs remain main growth engines
Positive trial results support longer-lasting product demand
Wider GLP-1 distribution increases potential customer reach
Recent pullback makes the price setup more reasonable for recovery

How it played out

LLY: target reached in 30 days, peak gain was 35.8%

Lyra published the LLY thesis on April 22, 2026, at $919.97, with expected growth of 15%. The thesis pointed to demand for obesity and diabetes drugs, positive trial results, wider GLP-1 distribution, and the recent pullback as support for a recovery.

The stock reached the $1,057.96 target in 30 days. It later peaked at $1,249.45 on July 7, a gain of 35.8%. It ended the window at $1,175.41, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On April 30, 2026, Lilly reported first-quarter revenue of $19.8 billion and raised its full-year revenue guidance. On June 7, 2026, the company reported weight-loss results from analyses of more than 1,500 women in two Foundayo trials.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals